Srs + retifanlimab + ragifilimab for glioblastoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 13 Jan 2020: Trial registered, NCT04225039
  2. 23 Jun 2020: Trial started, NCT04225039

The trials

NCT04225039: Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma

State
Under way
Phase
Phase 2
People
39 taking part
Started
23 Jun 2020
Primary completion
8 Sep 2022
Arms
Cohort A
Results
Posted on the registry
  1. 13 Jan 2020: Trial registered
  2. 23 Jun 2020: Trial started
  3. 15 Sep 2023: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.